Stalled Cerebral Capillary Blood Flow in Mouse Models of Essential Thrombocythemia

Size: px
Start display at page:

Download "Stalled Cerebral Capillary Blood Flow in Mouse Models of Essential Thrombocythemia"

Transcription

1 SUPPLEMENTAL MATERIAL Stalled Cerebral Capillary Blood Flow in Mouse Models of Essential Thrombocythemia and Polycythemia Vera Revealed by In Vivo Two-Photon Imaging Thom P. Santisakultarm, Claire Q. Paduano, Tracy Stokol, Teresa L. Southard, Nozomi Nishimura, Radek C. Skoda, William L. Olbricht, Andrew I. Schafer, Richard T. Silver, Chris B. Schaffer Page 1 of 7

2 Supplemental Figures and Legends Figure S1. Leukocyte and platelet counts did not predict cortical capillary stall rate. To test whether leukocytosis or thrombocytosis influence the rate of capillary stalls in murine models of mixed MPN, ET, PV or secondary erythrocytosis, we investigated the relationship between leukocyte and platelet counts and the rate of capillary stalls. Stall rate was dependent on neither leukocytosis (A) nor thrombocytosis (B). Shaded areas represent normal leukocyte and platelet counts in C57/Bl6 mice [1]. Previous clinical studies have had mixed findings on the influence of leukocyte and platelet counts on cardiovascular events [2-5]. Page 2 of 7

3 remaining capillary stalls (% of baseline) remaining capillary stalls (% of baseline) A B 1 leukocyte plug platelet aggregate remaining capillary stalls (% of baseline) remaining capillary stalls (% of baseline) C 1 stagnant RBCs D 1 empty mixed MPN BMT ET Epo-inj BMT PV Figure S2. Capillary stalls associated with leukocyte plugs, platelet aggregates, stagnant RBCs, and empty vessels in MPN mouse models reestablished blood flow at unequal rates. Our data suggests that cortical capillary stalls in MPN mouse models are long-lived. We further scrutinized the stall survival time in stalled capillaries where (A) leukocyte plugs, (B) platelet aggregates, (C) only RBCs, or (D) only blood plasma (i.e. no blood cells) were present. Individual stalled capillaries of all causes were monitored until blood flow reestablished, or for ~2 hours, whichever was first. The proportion of persistent leukocyte plugs, platelet aggregates, RBC stalls, and empty vessels decay over time at unequal rates in BMT mixed MPN, BMT ET, Epo-inj, and BMT PV mice. Notably, in the BMT ET group, over % of the stalls caused by platelet aggregates resolved quickly in the first 1 minutes. Because platelet plugs caused about half of the stalled capillaries in BMT ET mice, this fast resolution was reflected the shorter persistence of all stall types over time (see Figure 3D). Page 3 of 7

4 Figure S3. Capillary density in ET, PV, mixed MPN, and secondary erythrocytosis mouse models. (A) Density of capillary segments shows a large variability among animals within each group but no significant difference between groups. Page 4 of 7

5 Supplemental Tables Table S1. Number of Subjects in Each Measurement Stall Stall Stall Type Diameter Speed Persistence Capillary Density wt BMT wt BMT mixed MPN BMT ET Epo-inj BMT PV Multiple types of measurements were frequently made in the same animal (e.g. rate of capillary stalling, stall type, stall persistence) Page 5 of 7

6 Supplemental References 1 Green EL. Biology of the Laboratory Mouse Tefferi A. Platelet count in essential thrombocythemia: the more the better? Blood. 28; 112: /blood Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Risk factors for arterial and venous thrombosis in WHOdefined essential thrombocythemia: an international study of 891 patients. Blood. 211; 117: /blood Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 29; 114: /blood Gangat N, Strand JJ, Li C-Y, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. British Journal of Haematology. 27; 138: /j x. Page 6 of 7

7 Legends for the Video Files Video S1. 2PEF image stack from a BMT PV mouse. Capillaries with stalled blood flow are circled, with different colors indicating different causes of capillary stalls: stationary RBCs (red), platelet aggregate (green), leukocyte plug (blue), empty (white). The field of view of the image stack is 32 µm and the image frames are spaced by 1 µm along the z-axis. Page 7 of 7

Emerging diagnostic and risk stratification criteria

Emerging diagnostic and risk stratification criteria PV STATE OF MIND Polycythemia vera: Emerging diagnostic and risk stratification criteria Rami S. Komrokji, MD Moffitt Cancer Center, Tampa, Florida Disclosure These slides were developed by Incyte Corporation

More information

É. PÓSFAI 1, I. MARTON 1, B. KOTOSZ 2, Z. BORBÉNYI 1. Patients and Methods. Introduction

É. PÓSFAI 1, I. MARTON 1, B. KOTOSZ 2, Z. BORBÉNYI 1. Patients and Methods. Introduction European Review for Medical and Pharmacological Sciences 2015; 19: 1258-1263 Contribution of cardiovascular risk factors in the thrombotic complications of essential thrombocythaemia: a Hungarian single-institute

More information

Influence of platelet and white blood cell counts on major thrombosis analysis from a patient registry in essential thrombocythemia

Influence of platelet and white blood cell counts on major thrombosis analysis from a patient registry in essential thrombocythemia European Journal of Haematology 97 (511 516) ORIGINAL ARTICLE Influence of platelet and white blood cell counts on major thrombosis analysis from a patient registry in essential thrombocythemia Veronika

More information

John Nguyen, Nozomi Nishimura, Robert Fetcho, Costantino Iadecola, Chris B. Schaffer

John Nguyen, Nozomi Nishimura, Robert Fetcho, Costantino Iadecola, Chris B. Schaffer Supplemental figures and text for Occlusion of cortical ascending venules causes blood flow decreases, reversals in flow direction, and vessel dilation in upstream capillaries John Nguyen, Nozomi Nishimura,

More information

Masked polycythaemia vera: presenting features, response to treatment and. clinical outcomes. Running title: masked polycythaemia vera.

Masked polycythaemia vera: presenting features, response to treatment and. clinical outcomes. Running title: masked polycythaemia vera. Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes Running title: masked polycythaemia vera Alberto Alvarez-Larrán 1, Anna Angona 1, Agueda Ancochea 1, Francesc

More information

The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia

The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia Received: 3 February 2017 Revised: 13 February 2017 Accepted: 14 February 2017 DOI: 10.1002/ajh.24689 RESEARCH ARTICLE The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin

More information

Prognostic models in PV and ET

Prognostic models in PV and ET Prognostic models in PV and ET Francesco Passamonti Hematology, Varese, Italy Current risk stratification in PV and ET: statement from European LeukemiaNet consensus Age over 60 years Previuos thrombosis

More information

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? review Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Lorenzo Falchi, 1 Prithviraj Bose, 2 Kate J. Newberry 2 and Srdan Verstovsek

More information

Polycythemia vera: Emerging diagnostic and risk stratification criteria

Polycythemia vera: Emerging diagnostic and risk stratification criteria This article, sponsed by Incyte Cpation, is based on a paid interview with Rami S. Komrokji, MD, of Moffitt Cancer Center, Tampa, Flida, conducted on May 4, 2015. Polycythemia vera: Emerging diagnostic

More information

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study Published Ahead of Print on July 11, 2011 as 10.1200/JCO.2010.34.5298 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.5298 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E

More information

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia Intern Emerg Med (5) :5 6 DOI.7/s79-5-86-8 IM - ORIGINAL Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia Andrea Piccin Michael Steurer Manfred

More information

WHO Update to Myeloproliferative Neoplasms

WHO Update to Myeloproliferative Neoplasms WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories

More information

International Journal of Scientific & Engineering Research, Volume 8, Issue 12, December-2017 ISSN

International Journal of Scientific & Engineering Research, Volume 8, Issue 12, December-2017 ISSN ISSN 2229-5518 286 Overview of management strategies toward Thrombocythemia Mayada Amin Aljudaibi, Reem Ali Mohammed Alamoodi, Abrar Ali Mohammed Alamoodi, Samar Mohammed Hasan Al_Hashemi, Bashayer Sadagah

More information

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients Francesco Passamonti, 1 Elisa Rumi, 1 Luca Arcaini, 1 Emanuela Boveri, 2 Chiara Elena,

More information

Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches

Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches Margherita Maffioli, MD, Barbara Mora, MD, and Francesco Passamonti, MD Drs Maffioli and Mora are hematologists in

More information

Essential thrombocythemia treatment algorithm 2018

Essential thrombocythemia treatment algorithm 2018 Tefferi et al. (2018) 8:2 DOI 10.1038/s41408-017-0041-8 CURRENT TREATMENT ALGORITHM Essential thrombocythemia treatment algorithm 2018 Ayalew Tefferi 1, Alessandro M. Vannucchi 2 and Tiziano Barbui 3 Open

More information

Managing ET in Tiziano Barbui MD

Managing ET in Tiziano Barbui MD Managing ET in 2019 Tiziano Barbui MD (tbarbui@asst-pg23.it) Hematology and Foundation for Clinical Research, Hospital Papa Giovanni XXIII Bergamo, Italy Managing ET in 2019 Establish diagnosis Risk Stratification

More information

New WHO Classification of Myeloproliferative Neoplasms

New WHO Classification of Myeloproliferative Neoplasms New WHO Classification of Myeloproliferative Neoplasms Hans Michael Kvasnicka Senckenberg Institute of Pathology, University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Principles and rationale

More information

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of

More information

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera UNCORRECTED PROOF Original Investigation Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera Éva Pósfai, Imelda Marton, Zita Borbényi, Attila Nemes 2 nd

More information

European Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes A critical reappraisal of anagrelide in the management of ET

European Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes A critical reappraisal of anagrelide in the management of ET European Focus on Myeloproliferative Diseases and Myelodysplastic Syndromes 2012 Clinical i l Aspects of Polycythemia and Essential Thrombocythemia A critical reappraisal of anagrelide in the management

More information

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction? 1539 Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction? Kamya Sankar, MD, a and Brady L. Stein, MD, MHS a,b,c Abstract Polycythemia vera (PV) and essential thrombocythemia

More information

Why do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012

Why do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012 Why do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012 Outline Case presentation Overview of PV Disease course Mechanisms of thrombosis Case Presentation

More information

Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study*

Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study* Original papers Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study* Iwona Prajs A F, Kazimierz Kuliczkowski F Department and Clinic of Hematology, Blood

More information

Cytoreductive treatment patterns among US veterans with polycythemia vera

Cytoreductive treatment patterns among US veterans with polycythemia vera Parasuraman et al. BMC Cancer (2018) 18:528 https://doi.org/10.1186/s12885-018-4422-6 RESEARCH ARTICLE Open Access Cytoreductive treatment patterns among US veterans with polycythemia vera Shreekant Parasuraman

More information

Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era

Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era 1238 Original Research Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era Elizabeth M. Kander, MD a ; Alison R. Moliterno, MD b ; Alfred Rademaker,

More information

Volume 28, Issue 4 Fall 2018 eissn:

Volume 28, Issue 4 Fall 2018 eissn: Volume 28, Issue 4 Fall 2018 eissn: 2368-8076 Myeloproliferative neoplasms (MPNs) Part 1: An overview of the diagnosis and treatment of the classical MPNs by Sabrina Fowlkes, Cindy Murray, Adrienne Fulford,

More information

International Journal of Gerontology

International Journal of Gerontology International Journal of Gerontology 7 (2013) 40e44 Contents lists available at SciVerse ScienceDirect International Journal of Gerontology journal homepage: www.ijge-online.com Original Article JAK2 V617F

More information

Current Challenges in the Management of Essential Thrombocythemia

Current Challenges in the Management of Essential Thrombocythemia Current Challenges in the Management of Essential Thrombocythemia Ariel Kleman, MD, Arun K. Singavi, MD, Laura C. Michaelis, MD The authors are affiliated with the Medical College of Wisconsin in Milwaukee,

More information

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia https://doi.org/10.1186/s40164-018-0124-7 Experimental Hematology & Oncology RESEARCH Open Access The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia Yee Yee Yap 1,2*,

More information

Novel Therapeutic Approaches in Polycythemia Vera

Novel Therapeutic Approaches in Polycythemia Vera Novel Therapeutic Approaches in Polycythemia Vera Charles Elliott Foucar, MD, and Brady Lee Stein, MD, MHS The authors are affiliated with the Northwestern University Feinberg School of Medicine in Chicago,

More information

The spectrum of JAK2-positive myeloproliferative neoplasms

The spectrum of JAK2-positive myeloproliferative neoplasms THE SPECTRUM OF JAK2-POSITIVE MYELOPROLIFERATIVE NEOPLASMS:COMPLICATIONS AND THERAPEUTIC ADVANCES The spectrum of JAK2-positive myeloproliferative neoplasms Jean-Jacques Kiladjian 1 1 Saint-Louis Hospital

More information

Management of polycythaemia vera: a critical review of current data

Management of polycythaemia vera: a critical review of current data review Management of polycythaemia vera: a critical review of current data Mary F. McMullin, 1 Bridget S. Wilkins 2 and Claire N. Harrison 2 1 Centre for Cancer Research and Cell Biology, Queen s University,

More information

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,

More information

SPOTLIGHT SPOTLIGHT REVIEW. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

SPOTLIGHT SPOTLIGHT REVIEW. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia (2008) 22, 1494 1502 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $30.00 www.nature.com/leu REVIEW Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

More information

Blood Reviews 26 (2012) Contents lists available at SciVerse ScienceDirect. Blood Reviews. journal homepage:

Blood Reviews 26 (2012) Contents lists available at SciVerse ScienceDirect. Blood Reviews. journal homepage: Blood Reviews 26 (2012) 205 211 Contents lists available at SciVerse ScienceDirect Blood Reviews journal homepage: www.elsevier.com/locate/blre REVIEW Front-line therapy in polycythemia vera and essential

More information

The treatment of polycythaemia vera: an update in the JAK2 era

The treatment of polycythaemia vera: an update in the JAK2 era Intern Emerg Med (2007) 2:13 18 DOI 10.1007/s11739-007-0003-4 IM REVIEW G. Finazzi T. Barbui The treatment of polycythaemia vera: an update in the JAK2 era Received: 31 August 2006 / Accepted in original

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None JAK2, MPL and CALR Testing for Myeloproliferative Neoplasms Description Somatic (acquired) genetic variants in JAK2, MPL,

More information

Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche

Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche 41 CONGRESSO NAZIONALE SIE Bologna 14-17 Ottobre 2007 Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche Alessandro M. Vannucchi Dip.. di Ematologia, Università degli Studi

More information

Chronic Myeloproliferative Neoplasms: a Collaborative Approach

Chronic Myeloproliferative Neoplasms: a Collaborative Approach MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES www.mjhid.org ISSN 2035-3006 Review Chronic Myeloproliferative Neoplasms: a Collaborative Approach Lisa Pieri, Paola Guglielmelli and Alessandro

More information

Rischio emorragico e trombotico nella TE e PV

Rischio emorragico e trombotico nella TE e PV Convegno Interregionale SIE Delegazione Triveneto Approfondimento sulle sindromi mielodisplastiche e mieloproliferative Sessione: Sindromi Mieloproliferative Croniche Rischio emorragico e trombotico nella

More information

Research Article Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms

Research Article Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms Thrombosis Volume 2011, Article ID 874146, 8 pages doi:10.1155/2011/874146 Research Article Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms Brady L. Stein, 1 Alfred

More information

Hydroxyurea: the comparator in studies with new anti-jak2 inhibitors

Hydroxyurea: the comparator in studies with new anti-jak2 inhibitors Hematology Meeting Reports 2009;3(3):108 114 SESSION VIII xg. Finazzi T. Barbui 1 x Divisione di Ematologia e 1 Fondazione per la Ricerca Ospedali Riuniti di Bergamo, Italy Hydroxyurea: the comparator

More information

Manchester Cancer Haematological Oncology Pathway Board

Manchester Cancer Haematological Oncology Pathway Board Manchester Cancer Haematological Oncology Pathway Board Guidelines for the diagnosis and treatment of myeloproliferative neoplasms including: Polycythaemia vera Essential thrombocythaemia and Myelofibrosis

More information

Published in: Journal of Clinical Oncology. Document Version: Publisher's PDF, also known as Version of record

Published in: Journal of Clinical Oncology. Document Version: Publisher's PDF, also known as Version of record Hydroxycarbamide plus vs Alone in Patients with Essential Thrombocythaemia Aged 40-59 Years Without High-Risk Features Godfrey, A. L., Campbell, P. J., MacLean, C., Buck, G., Cook, J., Temple, J.,... Harrison,

More information

ORIGINAL ARTICLE. A Tefferi 1, TL Lasho 1, J Huang 1, C Finke 1, RA Mesa 1,CYLi 2,WWu 3, CA Hanson 2 and A Pardanani 1

ORIGINAL ARTICLE. A Tefferi 1, TL Lasho 1, J Huang 1, C Finke 1, RA Mesa 1,CYLi 2,WWu 3, CA Hanson 2 and A Pardanani 1 (28) 22, 756 76 & 28 Nature Publishing Group All rights reserved 887-6924/8 $3. www.nature.com/leu ORIGINAL ARTICLE, compared to either a higher allele burden or unmutated status, is associated with inferior

More information

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real world clinical practice: a chart review

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real world clinical practice: a chart review DOI 10.1186/s40164-016-0031-8 Experimental Hematology & Oncology RESEARCH Open Access Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real world clinical practice:

More information

Are patients with high risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real world data

Are patients with high risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real world data https://doi.org/10.1186/s40164-018-0107-8 Experimental Hematology & Oncology RESEARCH Open Access Are patients with high risk polycythemia vera receiving cytoreductive medications? A retrospective analysis

More information

ORIGINAL ARTICLE. European Journal of Haematology

ORIGINAL ARTICLE. European Journal of Haematology European Journal of Haematology ORIGINAL ARTICLE Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic

More information

CENTRO DI RICERCA E INNOVAZIONE PER LE MALATTIE MIELOPROLIFERATIVE (CRIMM) PUBBLICAZIONI

CENTRO DI RICERCA E INNOVAZIONE PER LE MALATTIE MIELOPROLIFERATIVE (CRIMM) PUBBLICAZIONI Pubblicazioni ultimi 3 anni del CRIMM Scotch AH, Kosiorek H, Scherber R, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res. 2017 Oct 14;63:34-40.

More information

Retrospective Study of High Hemoglobin Levels in 56 Young Adults

Retrospective Study of High Hemoglobin Levels in 56 Young Adults Original Article J Hematol. 2018;7(2):43-50 Retrospective Study of High Hemoglobin Levels in 56 Young Adults Alexandra Desnoyers a, Michel Pavic a, Paul-Michel Houle a, b, Jean-Francois Castilloux a, Patrice

More information

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria /, 2017, Vol. 8, (No. 60), pp: 101735-101744 Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria Elisa Rumi 1,2,

More information

Technical Bulletin No. 100

Technical Bulletin No. 100 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.

More information

Ruxolitinib for the treatment of patients with polycythemia vera

Ruxolitinib for the treatment of patients with polycythemia vera Ruxolitinib for the treatment of patients with polycythemia vera Jean-Jacques Kiladjian, Hôpital Saint-Louis & Université Paris Diderot Elliott Winton, Emory University Moshe Talpaz, University of Michigan

More information

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera CLINICAL IMPACT OF TARGETED THERAPIES IN MYELOPROLIFERATIVE NEOPLASMS Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera Claire Harrison 1 1 Guy

More information

Polycythemia Vera: Contemporary Updates in Diagnosis, Prognosis, and Treatment

Polycythemia Vera: Contemporary Updates in Diagnosis, Prognosis, and Treatment Polycythemia Vera: Contemporary Updates in Diagnosis, Prognosis, and Treatment Saba S. Shaikh, MD, and Brady L. Stein, MD, MHS Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm characterized

More information

Current and future treatment options for polycythemia vera

Current and future treatment options for polycythemia vera Ann Hematol (2015) 94:901 910 DOI 10.1007/s00277-015-2357-4 REVIEW ARTICLE Current and future treatment options for polycythemia vera Martin Griesshammer 1,4 & Heinz Gisslinger 2 & Ruben Mesa 3 Received:

More information

Chronic Myeloproliferative Disorders

Chronic Myeloproliferative Disorders 1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)

More information

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2

More information

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors OPEN Citation: (2015) 5, e366; doi:10.1038/bcj.2015.95 www.nature.com/bcj REVIEW Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: October 15, 2017 Related Policies: None JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms Description Somatic (acquired) genetic variants in JAK2, MPL,

More information

Brief Communication Diagnostic Hematology

Brief Communication Diagnostic Hematology Brief Communication Diagnostic Hematology Ann Lab Med 2015;35:233-237 http://dx.doi.org/10.3343/alm.2015.35.2.233 ISSN 2234-3806 eissn 2234-3814 Incidence, Clinical Features, and Prognostic Impact of CALR

More information

Supplementary Materials for

Supplementary Materials for www.sciencetranslationalmedicine.org/cgi/content/full/4/117/117ra8/dc1 Supplementary Materials for Notch4 Normalization Reduces Blood Vessel Size in Arteriovenous Malformations Patrick A. Murphy, Tyson

More information

Histological evaluation of myeloproliferative neoplasms

Histological evaluation of myeloproliferative neoplasms Journal of clinical and experimental hematopathology Vol. 58 No.2, 45-50, 2018 JC lin EH xp ematopathol Review Article Histological evaluation of myeloproliferative neoplasms Hideyo Fujiwara In 2017, the

More information

Polycythemia vera treatment algorithm 2018

Polycythemia vera treatment algorithm 2018 Tefferi et al. (2018) 8:3 DOI 10.1038/s41408-017-0042-7 CURRENT TREATMENT ALGORITHM Polycythemia vera treatment algorithm 2018 Ayalew Tefferi 1, Alessandro M. Vannucchi 2 and Tiziano Barbui 3 Open Access

More information

Elenco complessivo delle Pubblicazioni scientifiche a stampa della prof Maria Luigia Randi (Padova)

Elenco complessivo delle Pubblicazioni scientifiche a stampa della prof Maria Luigia Randi (Padova) Elenco complessivo delle Pubblicazioni scientifiche a stampa della prof Maria Luigia Randi (Padova) -Girolami A, Cella G, Dal Bo Zanon R, Cappellato G, RANDI ML: Aspirin and bleeding time. Lancet 1979;ii:205-206

More information

Mouse models of myeloproliferative neoplasms: JAK of all grades

Mouse models of myeloproliferative neoplasms: JAK of all grades Disease Models & Mechanisms 4, 311-317 (2011) doi:10.1242/dmm.006817 Mouse models of myeloproliferative neoplasms: JAK of all grades Juan Li 1, David G. Kent 1, Edwin Chen 1 and Anthony R. Green 1,2, In

More information

CLINICAL CASE PRESENTATION

CLINICAL CASE PRESENTATION European Winter School of Internal Medicine 2015 Riga, Latvia, 26-30 January CLINICAL CASE PRESENTATION Vasiliy Chulkov South Ural State Medical University (Chelyabinsk, Russia) CHELYABINSK CLINICAL HISTORY

More information

Clinical phenotype and prognosis of JAK2 and CALR mutation in Asian patients with Essential Thrombocythemia

Clinical phenotype and prognosis of JAK2 and CALR mutation in Asian patients with Essential Thrombocythemia Open Access Research Article Clinical phenotype and prognosis of JAK2 and CALR mutation in Asian patients with Essential Thrombocythemia Chin-Hin Ng 1 ; Zhaojin Chen * ; Christopher Ng 2 ; Elaine Seah

More information

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial Regular Article CLINICAL TRIALS AND OBSERVATIONS Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial Heinz Gisslinger, 1

More information

Department of Hematology, Sakarya University Training and Research Hospital, Sakarya, Turkey.

Department of Hematology, Sakarya University Training and Research Hospital, Sakarya, Turkey. Original Article Hematology Medical Journal of Islamic World Academy of Sciences doi: 10.5505/ias.2018.90093 2018;26(3): 59-64 Retrospective analysis of patients with chronic myeloproliferative neoplasms:

More information

İstanbul University, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey 5

İstanbul University, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey 5 Research Article 10.5505/tjh.2012.58751 The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms Philadelphia

More information

JAK inhibitors in Phmyeloproliferative

JAK inhibitors in Phmyeloproliferative Disclosures for A Pardanani Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board TargeGen, Cytopia/YM BioSciences, PharmaMar None None None None None Presentation

More information

Disclosures for Ayalew Tefferi

Disclosures for Ayalew Tefferi Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte

More information

Myeloproliferative neoplasia: a review of clinical criteria and treatment

Myeloproliferative neoplasia: a review of clinical criteria and treatment REVIEW Myeloproliferative neoplasia: a review of clinical criteria and treatment S.M. Koopmans* 1, A.M.W. van Marion 2, H.C. Schouten 3 1 Department of Pathology of the University Hospital Maastricht,

More information

Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? Hematologic Malignancies Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? AZIZ NAZHA, AARONT. GERDS Leukemia Program, Department of Hematology and Medical Oncology, Taussig

More information

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease The Internists Approach to Polycythemia and Implications of Uncontrolled Disease Mary Jo K. Voelpel, DO, FACOI, MA, CS Associate Clinical Professor MSU-COM Disclosures NONE Overview 1. Objectives 2. Case

More information

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients Brief Report Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients Elisa Rumi, 1 Francesco Passamonti, 1 Chiara Elena, 1 Daniela Pietra, 1 Luca Arcaini,

More information

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis Current Hematologic Malignancy Reports https://doi.org/10.1007/s11899-018-0453-y MYELOPROLIFERATIVE NEOPLASMS (B STEIN, SECTION EDITOR) Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis

More information

ASBMT MDS/MPN Update Sunil Abhyankar, MD

ASBMT MDS/MPN Update Sunil Abhyankar, MD ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine

More information

New Perspectives on Polycythemia Vera: Overcoming Challenges in Diagnosis, Risk Assessment, and Disease Management

New Perspectives on Polycythemia Vera: Overcoming Challenges in Diagnosis, Risk Assessment, and Disease Management New Perspectives on Polycythemia Vera: Overcoming Challenges in Diagnosis, Risk Assessment, and Disease Management Jorge E. Cortes, MD The University of Texas MD Anderson Cancer Center Houston, Texas Francesco

More information

Triple Negative Myeloproliferative Neoplasms - Sometimes Driver Mutations Stay Low-Key in Plain Sight

Triple Negative Myeloproliferative Neoplasms - Sometimes Driver Mutations Stay Low-Key in Plain Sight Romanian Biotechnological Letters Vol., No. x, Copyright 2017 University of Bucharest Printed in Romania. All rights reserved ORIGINAL PAPER Triple Negative Myeloproliferative Neoplasms - Sometimes Driver

More information

Polycythemia Vera and Essential Thombocythemia A Single Institution Experience

Polycythemia Vera and Essential Thombocythemia A Single Institution Experience INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 29 No 4, 2008 7 Original Article-I Polycythemia Vera and Essential Thombocythemia A Single Institution Experience CECIL ROSS, NAVYA, VANAMALA AND KARUNA

More information

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia MYELOPROLIFERATIVE DISORDERS New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia Ross L. Levine 1,2 and Mark Heaney 2 1 Human Oncology and Pathogenesis Program; 2 Leukemia Service,

More information

CASE REPORT. Abstract. Introduction

CASE REPORT. Abstract. Introduction CASE REPORT The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation Kazuhiko Ikeda 1,2,

More information

Molecular Diagnostics for Myeloproliferative Neoplasms. Noah Brown, MD April 16, 2015

Molecular Diagnostics for Myeloproliferative Neoplasms. Noah Brown, MD April 16, 2015 Molecular Diagnostics for Myeloproliferative Neoplasms Noah Brown, MD April 16, 2015 Outline 1. Brief MPN Introduction 2. When/How Should Molecular Testing be Performed? 3. JAK2 V617F Mutation Testing

More information

Current Prognostication in Primary Myelofibrosis

Current Prognostication in Primary Myelofibrosis Current Prognostication in Primary Myelofibrosis Francisco Cervantes Hematology Department, Hospital Clínic, Barcelona, Spain Florence, April 2011 Survival in PMF No. patients: 1,054 Median Srv (95% CI):

More information

THE ROLE OF JAK2 MUTATION IN THROMBOTIC COMPLICATIONS OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS

THE ROLE OF JAK2 MUTATION IN THROMBOTIC COMPLICATIONS OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS THE ROLE OF JAK2 MUTATION IN THROMBOTIC COMPLICATIONS OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS *Viola M. Popov, 1 Minodora Onisai, 2 Mihaela Găman, 2 Ana Maria Vladareanu 2 1. Hematology Department, Colentina

More information

J Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION VOLUME 29 NUMBER 4 FEBRUARY 1 11 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates

More information

Patient Case Studies & Panel Discussion Myeloproliferative Disorders, Elderly Myelofibrosis, Hemophagocytic Syndromes

Patient Case Studies & Panel Discussion Myeloproliferative Disorders, Elderly Myelofibrosis, Hemophagocytic Syndromes Patient Case Studies & Panel Discussion Myeloproliferative Disorders, Elderly Myelofibrosis, Hemophagocytic Syndromes Panelists: Jessica Altman, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern

More information

Clinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera

Clinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera Clinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera Alessandro M. Vannucchi, MD Laboratorio Congiunto MMPC Department of Experimental and Clinical Medicine University

More information

Mutaciones y sus implicancias clínicas en neoplasias mieloproliferativas

Mutaciones y sus implicancias clínicas en neoplasias mieloproliferativas Mutaciones y sus implicancias clínicas en neoplasias mieloproliferativas Genetics and prognosis in myeloproliferative neoplasms Guglielmelli P, Rotunno G, Pacilli A, Vannucchi AM NEOPLASIAS MIELOPROLIFERATIVAS

More information

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy François Girodon, 1,2 Céline Schaeffer, 1 Cédric Cleyrat,

More information

An elevated hematocrit or platelet count in an otherwise

An elevated hematocrit or platelet count in an otherwise The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis Marco Ruggeri, MD; Alberto Tosetto, MD; Maurizio Frezzato, MD; and Francesco

More information

Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis

Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis Research Article Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis I. Mignon, 1 F. Grand, 1 F. Boyer, 2 M. Hunault-Berger, 2 J.F.

More information

Focus on aggressive polycythemia vera

Focus on aggressive polycythemia vera Focus on aggressive polycythemia vera Jerry L. Spivak, MD Professor of Medicine and Oncology Director, the Johns Hopkins Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School

More information

ORIGINAL ARTICLE. The JAK2 V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels

ORIGINAL ARTICLE. The JAK2 V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels ORIGINAL ARTICLE The JAK2 V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels Giuseppe Tagariello, Rosanna Di Gaetano, Roberto Sartori, Daniela Zanotto, Donata Belvini, Paolo

More information

Received: 19 September 2009 / Accepted: 28 December 2009 / Published online: 10 February 2010 # Springer-Verlag 2010

Received: 19 September 2009 / Accepted: 28 December 2009 / Published online: 10 February 2010 # Springer-Verlag 2010 Ann Hematol (2010) 89:691 699 DOI 10.1007/s00277-009-0899-z Author manuscript, published in "Annals of Hematology 89, 7 (2010) 691-699" DOI : 10.1007/s00277-009-0899-z ORIGINAL ARTICLE A retrospective

More information

How I Treat. How I treat polycythemia vera. Introduction. Alessandro M. Vannucchi

How I Treat. How I treat polycythemia vera. Introduction. Alessandro M. Vannucchi How I Treat From www.bloodjournal.org by guest on September 6, 2018. For personal use only. How I treat polycythemia vera Alessandro M. Vannucchi Laboratorio Congiunto Malattie Mieloproliferative Croniche,

More information